Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06609876
NA

Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC

Sponsor: Sun Yat-sen University

View on ClinicalTrials.gov

Summary

This study intends to evaluate the efficacy and safety of low-dose adjuvant donafenib after thermal ablation for early recurrent HCC within Milan criteria.

Official title: Thermal Ablation Combined With Low-dose Donafinib for Early Recurrent Hepatocellular Carcinoma: a Multicenter Prospective Study

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

108

Start Date

2024-10-01

Completion Date

2028-10-01

Last Updated

2024-12-03

Healthy Volunteers

No

Interventions

PROCEDURE

Thermal ablation

Thermal ablation of tumors

DRUG

Donafenib

Donafenib ( 100 mg,bid)

Locations (1)

Chinese PLA General hospital

Beijing, None Selected, China